Medication-Related Osteonecrosis of the Jaws (MRONJ): Primordial Project

The rationale behind this project:


Antiresorptive drugs such as bisphosphonates and denosumab are widely used to treat cancer and osteoporosis but can unfortunately lead to Medication-Related Osteonecrosis of the Jaws (MRONJ). This condition involves persistent exposure of necrotic bone in the mouth for over eight weeks and may cause pain, infection, or fistula.


Our doctoral projects aim to identify radiographic and genetic risk factors for MRONJ and develop an AI-driven radiomics prediction model. Besides, we aim to assess whether Leukocyte-Platelet Rich Fibrin (L-PRF) can help prevent MRONJ after tooth extraction, as well as determine the most effective treatment strategies.

CONTACT:

Published articles:


Understanding the genetic basis of medication-related osteonecrosis of the jaw: A systematic review. 


Radi S, Jans DS, Moreno-Rabié C, Beuselinck B, Cleynen I, Jacobs R. Understanding the genetic basis of medication-related osteonecrosis of the jaw: A systematic review. Bone. 2025 Dec;201:117623. PMID: 40921376.




Alveolar socket surface area as a local risk factor for MRONJ development in oncologic patients on polypharmacy


Gracea RS, Suryani IR, Fontenele RC, Gaêta-Araujo H, Radi S, Elgarba BM, Shujaat S, Coropciuc R, Jacobs R. Alveolar socket surface area as a local risk factor for MRONJ development in oncologic patients on polypharmacy. Clin Oral Investig. 2025 Feb 8;29(2):123. PMID: 39920415




Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement


Coropciuc R, Moreno-Rabié C, De Vos W, Van de Casteele E, Marks L, Lenaerts V, Coppejans E, Lenssen O, Coopman R, Walschap J, Nadjmi N, Jacobs R, Politis C, Van den Wyngaert T. Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement. Acta Chir Belg. 2024 Feb;124(1):1-11. PMID: 38059301




Risk of healing impairment following tooth extraction in patients administered with antiresorptive and non-antiresorptive polypharmacy


Suryani IR, Shujaat S, Ivković U, Coucke W, Coropciuc R, Jacobs R. Risk of healing impairment following tooth extraction in patients administered with antiresorptive and non-antiresorptive polypharmacy. J Stomatol Oral Maxillofac Surg. 2024 Apr;125(2):101645. PMID: 37748709




Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients


Coropciuc R, Coopman R, Garip M, Gielen E, Politis C, Van den Wyngaert T, Beuselinck B. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients. Bone. 2023 May;170:116722. PMID: 36858337




Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review


Moreno-Rabié C, Gaêta-Araujo H, Oliveira-Santos C, Politis C, Jacobs R. Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review. Clin Oral Investig. 2020 Sep;24(9):2973-2989. doi: 10.1007/s00784-020-03423-0. Epub 2020 Jul 6. PMID: 32627123.



Privacy policy

OK